Tryptase is a tetrameric serine protease which is stored almost exclusively in the secretory granules of mast cells. Substantial quantities of this enzyme are released as a consequence of mast cell activation in allergic disease. The pathobiological role of tryptase is not well understood, though this enzyme can cleave a number of potential substrates [reviewed in ref. 1]. Tryptase can efficiently degrade certain regulatory peptides including the bronchodilator, vasoactive intestinal peptide and the potent vasodilator cal-citonin-gene-related peptide; it may have a role in kinin generation, and by activating stromelysin, it may participate in processes of tissue degradation, and it can act as a growth factor for fibroblasts. Microvascular leakage has been observed in the skin of guinea pigs following injection of purified human mast cell tryptase. As we have found that the increase in vascular permeability can be inhibited by antihistamine pretreatment, and that tryptase can stimulate histamine release from guinea pig mast cells in vitro, it would seem likely that the effect is mediated by tryptaseinduced mast cell activation. Injection of tryptase into guinea pig skin or the mouse peritoneum results, within 6 h, in a neutrophil-rich inflammatory infiltrate. We have investigated potential mechanisms of human granulocyte recruitment by tryptase using in vitro models. In modified Boyden chambers with neutrophils purified from peripheral blood on Lymphoprep, we have found that tryptase can itself act as a chemoattractant even at concentrations of 6 mU/ml (where 1 mU is defined as that amount which can hydrolyse 1 nmol of the peptide substate N-α-benzoyl-DI-arginine /?-nitroanilide per minute at 25 °C). This action was inhibited by protease inhibitors including leupeptin, and by heat treatment, indicating dependence on an active catalytic site. Incubation of purified neutrophils with tryptase was associated with a shape change reaction within minutes, as revealed by scanning electron microscopy.
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